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1. Introduction 
Cytochrome P-450, the key liver endoplasmic 
reticulum protein playing a vital role in drug metab- 
olism, undergoes marked changes in level under a 
wide variety of conditions [1,2]. While information 
is available on the effect of drugs on the synthesis 
and turnover of cytochrome P-450-heme [3,4], very 
little is known about he synthesis of the apo-protein 
species under these conditions. Recent attempts to 
evaluate the rate of apo-cytochrome P-450 synthesis 
have essentially involved the measurement of the rate 
of labeled amino acid incorporation i to a protein 
band on SDS-acrylamide gels, which includes the 
species of cytochrome P-450 [5,6]. In the present 
study, antibody has been raised to cytochrome P-450, 
purified from the livers of phenobarbital-treated rats 
and this antibody has been used to follow the rate of 
synthesis of this protein in vivo and in a cell-free 
system from the livers of rats subjected to treatments 
which are known to alter the content of this protein. 
2. Experimental 
Cytochrome P-450 was purified from the livers of 
phenobarbital-treated rats as in [7]. For this purpose 
male rats (60-70 g) which had received affy injec- 
tions of phenobarbital (80 mg/kg) for 4 days were 
used. The final cytochrome P-450 preparation had a 
specific heme content of 17 nmol heme/mg protein. 
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Antibody was raised in rabbits against he puri- 
fied cytochrome P-450 preparation and the schedule 
of antigen injection was as in [8]. 1 mg immuno- 
globulin G fraction was found to quantitatively pre- 
cipitate 45/ag purified cytochrome P-450 preparation. 
To measure cytochrome P-450 synthesis in vivo, 
30/aCi ~4C-labeled Chlorella protein hydrolysate was 
injected intraperitoneally into rats at different time 
intervals after suitable drug treatments. The schedule 
of drug injections is described in the appropriate 
figure and tables. The animals were killed 1 h after 
the tracer administration. The microsomal pellet 
(about 20 mg protein) was solubilized in 4 ml 0.1 M 
sodium phosphate buffer (pH 7.4) containing 20% 
glycerol, 1 mM EDTA and 1% cholate and the clear 
solution was centrifuged at 2500 rev./min for 
15 min. To 0.3 ml (2 mg protein) of the soluble 
preparation 0.4 ml immunoglobulin G fraction 
representing 2-fold excess of antibody was added. 
The incubation mixture also contained 0.5 mM 
phenylmethyl sulfonyl fluoride. The mixture was 
incubated at room temperature for 1 h and then at 
4°C overnight. The immunoprecipitate was collected 
by centrifugation a d suspended in 0.4 ml saline. 
The suspension was layered over 1 ml 0.5 M sucrose 
containing 1% deoxycholate in 20 mM Tris-HC1 
(pH 7.5) buffer and centrifuged. The pellet was 
dissolved in formic acid and plancheted on fffter 
paper discs for radioactivity measurement. 
Protein synthesis in vitro was studied using the 
post-mitochondrial supernatant. The preparation and 
assays conditions were as in [9]. 
At the end of the incubation, the mixture was 
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solubilized and ahquots were taken for precipitation 
with trichloroacetic a id and for treatment with the 
antibody after the addition of carrier cytochrome 
P-450. 
Antibody to bovine serum albumin was used to 
measure non-specific precipitation i the in vivo and 
in vitro experiments. Non-specific precipitation 
accounted for about 10% radioactivity in the immuno- 
precipitate. Some of the immunoprecipitation experi- 
ments were cross-checked using monospecific antibody 
to cytochrome/'-450. The preparation was based on 
the general procedure in [10]. Protein was estimated 
as in [11] using bovine serum albumin as the standard. 
Radioactivity measurements were made in a Beckman 
LS-100 liquid scintillation counter using 0.5% PPO in 
toluene as the scintillant. 
3. Results and discussion 
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Fig. 1. Radioactivity proffie of the cytochrome P-450 immuno- 
precipitate on SDS-gels. 30 uCi 14C-labeled Chlorella protein 
hydrolysate was injected to rats 12 h after a single injection of 
phenobarbital. The immunoprecipitation wascarried out using 
solubilized microsomal preparations and anti-PB-P-450 as 
described inthe text. Electrophoresis was carried out as in [ 16 ]. 
The immunoglobulin G fraction (anti-PB-P-450) 
isolated from rabbits immunized against purified cyto- 
chrome P-450 from phenobarbital-treated ratswas 
found to be quite specific and reacted weakly in 
Ouchterlony plates with purified cytochrome P-448 
preparations from 3-methyl cholanthrene-treated rats, 
as already demonstrated in [12]. The use of anti-PB- 
P-450 for immunoprecipitating cytochrome P-450 
from microsomal preparations labeled in vivo and 
in vitro was examined by subjecting the immuno- 
precipitate to SDS-acrylamide gel electrophoresis. 
The results in fig.1 indicate a single prominent 
radioactive peak in the cytochrome P-450 region. This 
pattern was quite similar and reproducible for the 
preparations obtained from in vivo and in vitro experi- 
ments, when the monospecific antibody was used. The 
use of immunoglobulin G fraction as such for precipita- 
tion sometimes resulted in the detection of low molec- 
ular weight proteins on the gel. However, this could be 
suppressed by the inclusion of the protease inhibitor 
phenyl methylsulphonyl fluoride and the immuno- 
precipitable radioactivity recovered with both antibody 
preparations was similar. 
In the in vivo experiments, a labeling period of 1 h 
was employed and the results have been taken to 
essentially represent the rate of cytochrome P-450 
synthesis. However, a striking change in the rate of 
degradation of the protein under conditions of drug 
treatments contributing to the net incorporation i to 
cytochromeP-450 is not ruled out. Therefore addition- 
al confirmation has been obtained by measuring the 
rate of cytochrome P-450 synthesis n vitro using the 
post-mitochondrial supernatant obtained from the 
livers of animals given the different drug treatments. 
In these in vitro experiments, essentially the already 
initiated protein chains are completed and would thus 
reflect he effect of the drug on the rate of protein 
synthesis. Differential degradation fcytochrome P-450 
in the in vitro experiments is unlikely in view of the 
similar recoveries in the immunoprecipitates obtained 
from labeled solubilized microsomes added to different 
preparations of the post-mitochondrial supernatant 
incubated under conditions of protein synthesis. 
The rate of cytochrome P-450 synthesis was exam- 
ined at different ime intervals after the administration 
of phenobarbital to rats. The rate of synthesis was 
determined both in vivo and in vitro using anti-PB- 
P-450 for immunoprecipitation. Representative experi- 
ments were cross-checked using the monospecific anti- 
body. The results presented in table 1 indicate that 6 h 
after phenobarbital dministration there is nearly a 
2-fold increase in the rate of cytochrome P-450 
synthesis. Maximum rate of synthesis i observed at 
12 h after phenobarbital dministration. A similar 
pattern of results is obtained in vivo and in vitro. The 
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Table 1 
Rate of cytochrome P-450 synthesis n vivo and in vitro after phenobarbital dministration 
May 1978 
Time (h) after Cytochrome P-450 synthesis 
phenobarbital 
administration In vivo In vitro 
Total micro- Cytochrome P-450 Total Cytochrome P-450 
somal protein (% total micro- protein (% total protein) 
(cpm/mg protein) somal protein) (cpm/mg protein) 
0 19 671 3.8 14 745 0.98 
6 21 735 6.4 15 625 1.52 
12 23 523 15.0 17 326 3.61 
18 22 625 7.8 17 459 1.54 
The in vitro synthesis was carried out with the S-17 liver fraction as in [ 10]. The incubation mixture in 1 ml 
contained: 20 mM Tris-HC1, pH 7.5, 60 mM KC1, 5 mM MgCI2, 75 mM sucrose, 1 mM DTT, 1.6 mM ATP, 0.6 mM 
GTP, 10 mM phosphoenolpyruvate, 40 t~g pyruvate kinase, 25 ~M each of 19 amino acids, 10 #Ci [3H]leucine and 
0.2 ml S- 17 fraction. The mixture was incubated for 20 min at 28°C. The other experimental details are given in text 
Table 2 
Effect of actinomycin D and 3-amino-l,2,4-triazole n the rate of 
cytochrome P-450 synthesis 
Treatment 
Cytochrome P-450 synthesis 
(% total protein) 
In vivo In vitro 
Saline 3.50 0.96 
Phenobarbital (12 h) 15.20 3.61 
Actinomycin D (12 h) 3.10 0.99 
Phenobarbital (12 h) 
+ actinomycin D (12 h) 6.40 0.89 
Phenobarbital (16 h) 11.20 
3-Amino-l,2,4-triazole (16 h) 2.90 
Phenobarbital (16 h) 
+ 3-amino-l,2,4-triazole (16 h) 6.40 
Phenobarbital (16 h) 
+ 3-amino-l,2,4-triazole (16 h) 





Actinomycin D (1.5 mg/kg) or 3-amino-l,2,4-triazole (3 g/kg) was injected 
intraperitoneally 15min before phenobarbital (80 mg/kg) administration. 
Actinomycin D injection was repeated 6 h after the first. Hemin (20 mg/kg) was 
injected before the administration f the label. The animals were killed at the 
time intervals indicated. The other experimental details are given in text 
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effect of  phenobarbital has also been confirmed in 
in vivo experiments, where the labeling period was 
reduced to 15 min (data not presented). 
Actinomycin D and 3-amino-1,2,4-triazole, an 
inhibitor of  heme synthesis, have been reported to 
block the increase in the content of  cytochrome P-450 
induced by phenobarbital [13,14]. In the present 
study the effects of these two inhibitors on the rate 
of  cytochrome P-450 synthesis were studied after 
phenobarbital dministration. The results presented in 
table 2 indicate that at the time intervals examined, 
both actinomy cin D and 3-amin o- 1,2,4-t riazole b ring 
about a significant decrease in the rate of cytochrome 
P-450 synthesis. The effect of 3-amino-1,2,4°triazole is 
counteracted partially by the administration of  
exogenous hemin. It it likely that the effect of  pheno- 
barbital on cytochrome P-450 synthesis is mediated 
through enhanced RNA synthesis and that prolonged 
inhibition of  heme synthesis would decrease the rate of  
apo-protein synthesis. It'has recently been suggested 
that heme is possibly not directly involved in the 
binding of  this protein to the endoplasmic reticutum 
[15]. 
Studies are in progress to examine the site ofheme 
action and quantitation of cytochrome P-450 
messenger RNA. 
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